Beone Medicines Ltd. splits its revenue into 8 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $5.3 billion, 99% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6,606
|
5,343
|
3,810
|
2,459
|
1,416
|
1,176
|
309
|
428
|
198
|
238
|
1
|
| Product |
6,499
+32.0%
share 98.4%
|
5,282
+39.8%
share 98.9%
|
3,780
+72.6%
share 99.2%
|
2,190
+74.5%
share 89.1%
|
1,255
+97.9%
share 88.6%
|
634
+105.3%
share 53.9%
|
309
+38.8%
share 100.0%
|
223
+70.1%
share 52.0%
|
131
+435.8%
share 66.0%
|
24
share 10.2%
|
—
|
| License |
—
|
—
|
—
|
—
|
—
|
485
share 41.2%
|
—
|
—
|
—
|
—
|
—
|
| License Revenue |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
211
share 88.7%
|
—
|
| Collaboration Other |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
150
share 35.0%
|
—
|
—
|
—
|
| Other Revenue |
108
+120.0%
share 1.6%
|
61
+98.6%
share 1.1%
|
31
-88.6%
share 0.8%
|
269
+66.7%
share 10.9%
|
161
share 11.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Collaboration Research And Development Service |
—
|
—
|
—
|
—
|
—
|
54
share 4.6%
|
—
|
28
+165.0%
share 6.5%
|
11
+311.2%
share 5.3%
|
3
share 1.1%
|
—
|
| Collaboration Reimbursement Of Research And Development Costs |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
28
-51.3%
share 6.5%
|
57
share 28.6%
|
—
|
—
|
| Right To Access Intellectual Property Revenue |
—
|
—
|
—
|
—
|
—
|
4
share 0.3%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONC (Nasdaq), BEIGF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Basel
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1651308
- Former names
- BeiGene, Ltd. (until May 27, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.